Actively Recruiting
Study to Test Roflumilast Foam 0.3% for Treating Children and Teens With Non-Segmental Vitiligo
Led by Derm Texas, PLLC · Updated on 2025-08-08
20
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of Roflumilast foam 0.3% in children and adolescents with Non-Segmental Vitiligo NSV, a condition causing skin depigmentation. This open-label, single-center, proof of concept study focuses on pediatric patients aged 2 to 18 years. The primary goal is to assess how many patients achieve at least 50% improvement in facial Vitiligo Area Scoring Index F-VASI at 24 weeks. Participants will apply Roflumilast 0.3% topical foam during the study. This treatment is being studied in a single group without a placebo comparison. The study lasts for 24 weeks, during which patients will regularly use the foam and undergo evaluations to track changes in their vitiligo. Throughout the study, participants will have visits at baseline and at weeks 4, 8, 12, 18, and 24. Researchers will measure skin changes using various Vitiligo Area Scoring Index scores and patient assessments such as the Patient Global Impression of Change-Vitiligo and Vitiligo Noticeability Scale. The study also monitors safety and adherence to treatment. The total participation time is approximately 24 weeks.
CONDITIONS
Brief Title
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
Research Team
A
Amanda Harvey, Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here